Detalhe da pesquisa
1.
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
J Neurooncol
; 144(2): 303-311, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31392595
2.
MB0 and MBI Are Independent and Distinct Transactivation Domains in MYC that Are Essential for Transformation.
Genes (Basel)
; 8(5)2017 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28481271
3.
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
J Thorac Oncol
; 5(6): 862-6, 2010 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-20521352
4.
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
Cancer J
; 16(1): 70-5, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20164695